{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:42:20Z","timestamp":1773816140112,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11033-022-07567-y","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:26:24Z","timestamp":1655465184000},"page":"7567-7573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["NTRK2 gene fusions are uncommon in pilocytic astrocytoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Daniel Antunes","family":"Moreno","sequence":"first","affiliation":[]},{"given":"Aline Paix\u00e3o","family":"Becker","sequence":"additional","affiliation":[]},{"given":"Cristovam","family":"Scapulatempo-Neto","sequence":"additional","affiliation":[]},{"given":"Weder","family":"Menezes","sequence":"additional","affiliation":[]},{"given":"Jamie","family":"Sheren","sequence":"additional","affiliation":[]},{"given":"Aline M","family":"Walter","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Clara","sequence":"additional","affiliation":[]},{"given":"H\u00e9lio R.","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Ricardo S.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Luciano","family":"Neder","sequence":"additional","affiliation":[]},{"given":"Marileila","family":"Varella-Garcia","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-7940","authenticated-orcid":false,"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"7567_CR1","doi-asserted-by":"publisher","first-page":"IV1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G et al (2020) CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neurooncology 22:IV1\u2013IV96. https:\/\/doi.org\/10.1093\/neuonc\/noaa200","journal-title":"Neurooncology"},{"key":"7567_CR2","unstructured":"National Cancer Institute Jos\u00e9 Alencar Gomes da Silva (INCA) (2013) Cancer in Brazil - Data from the Population Based Registries. In: ISBN 978-85-7318-221-7. https:\/\/www.inca.gov.br\/sites\/ufu.sti.inca.local\/files\/media\/document\/cancer-in-brazil-vol4-2013.pdf. Accessed 6 Dec 2021"},{"key":"7567_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"7567_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/NEUONC\/NOAB106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Ellison DA D (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/NEUONC\/NOAB106","journal-title":"Neuro Oncol"},{"key":"7567_CR5","doi-asserted-by":"crossref","unstructured":"Collins KL, Pollack IF (2020) Pediatric low-grade gliomas. Cancers (Basel) 12","DOI":"10.3390\/cancers12051152"},{"key":"7567_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","volume":"129","author":"VP Collins","year":"2015","unstructured":"Collins VP, Jones DTW, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:775\u2013788","journal-title":"Acta Neuropathol"},{"key":"7567_CR7","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s00018-011-0898-9","volume":"69","author":"DTW Jones","year":"2012","unstructured":"Jones DTW, Gronych J, Lichter P et al (2012) MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 69:1799\u20131811","journal-title":"Cell Mol Life Sci"},{"key":"7567_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.humpath.2018.06.005","volume":"80","author":"D Chatterjee","year":"2018","unstructured":"Chatterjee D, Garg C, Singla N, Radotra BD (2018) Desmoplastic non-infantile astrocytoma\/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation. Hum Pathol 80:186\u2013191. https:\/\/doi.org\/10.1016\/j.humpath.2018.06.005","journal-title":"Hum Pathol"},{"key":"7567_CR9","doi-asserted-by":"publisher","unstructured":"Breton Q, Plouhinec H, Prunier-Mirebeau D et al (2017) BRAF-V600E immunohistochemistry in a large series of glial and glial\u2013neuronal tumors. Brain and Behavior 7. https:\/\/doi.org\/10.1002\/brb3.641","DOI":"10.1002\/brb3.641"},{"key":"7567_CR10","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1200\/JCO.2014.59.9217","volume":"33","author":"A Gajjar","year":"2015","unstructured":"Gajjar A, Bowers DC, Karajannis MA et al (2015) Pediatric brain tumors: Innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol 33:2986\u20132998","journal-title":"J Clin Oncol"},{"key":"7567_CR11","doi-asserted-by":"publisher","unstructured":"Guidi M, Giunti L, Buccoliero A et al (2021) Genetic signature and treatment of pediatric highgrade glioma. Mol Clin Oncol 14. https:\/\/doi.org\/10.3892\/mco.2021.2232","DOI":"10.3892\/mco.2021.2232"},{"key":"7567_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/S00381-019-04282-1","volume":"35","author":"H Kurani","year":"2019","unstructured":"Kurani H, Gurav M, Shetty O et al (2019) Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups. Childs Nerv Syst 35:1525\u20131536. https:\/\/doi.org\/10.1007\/S00381-019-04282-1","journal-title":"Childs Nerv Syst"},{"key":"7567_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ng.2611","volume":"45","author":"J Zhang","year":"2013","unstructured":"Zhang J, Wu G, Miller CP et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602\u2013612. https:\/\/doi.org\/10.1038\/ng.2611","journal-title":"Nat Genet"},{"key":"7567_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/NEN.0000000000000213","volume":"74","author":"AP Becker","year":"2015","unstructured":"Becker AP, Scapulatempo-Neto C, Carloni AC et al (2015) KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas. J Neuropathol Exp Neurol 74:743\u2013754. https:\/\/doi.org\/10.1097\/NEN.0000000000000213","journal-title":"J Neuropathol Exp Neurol"},{"key":"7567_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ng.2682","volume":"45","author":"DTW Jones","year":"2013","unstructured":"Jones DTW, Hutter B, J\u00e4ger N et al (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927\u2013932. https:\/\/doi.org\/10.1038\/ng.2682","journal-title":"Nat Genet"},{"key":"7567_CR16","doi-asserted-by":"publisher","unstructured":"Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8. https:\/\/doi.org\/10.1186\/S40478-020-00902-Z","DOI":"10.1186\/S40478-020-00902-Z"},{"key":"7567_CR17","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.18632\/oncotarget.26777","volume":"10","author":"M Tuna","year":"2019","unstructured":"Tuna M, Amos CI, Mills GB (2019) Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. Oncotarget 10:2095\u20132111","journal-title":"Oncotarget"},{"key":"7567_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.cd-16-1237","volume":"7","author":"A Drilon","year":"2017","unstructured":"Drilon A, Hornby Z, Bencardino K et al (2017) Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7:400\u2013409. https:\/\/doi.org\/10.1158\/2159-8290.cd-16-1237","journal-title":"Cancer Discov"},{"key":"7567_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/nejmoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children. N Engl J Med 378:731\u2013739. https:\/\/doi.org\/10.1056\/nejmoa1714448","journal-title":"N Engl J Med"},{"key":"7567_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/NRD.2018.226","volume":"18","author":"A Mullard","year":"2018","unstructured":"Mullard A (2018) FDA approves landmark tissue-agnostic cancer drug. Nat Rev Drug Discov 18:7. https:\/\/doi.org\/10.1038\/NRD.2018.226","journal-title":"Nat Rev Drug Discov"},{"key":"7567_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5903863","volume":"2020","author":"SS Pattwell","year":"2020","unstructured":"Pattwell SS, Konnick EQ, Liu YJ et al (2020) Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature. Case Rep Pathol 2020:1\u20137. https:\/\/doi.org\/10.1155\/2020\/5903863","journal-title":"Case Rep Pathol"},{"key":"7567_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/nan.12503","volume":"45","author":"GY L\u00f3pez","year":"2019","unstructured":"L\u00f3pez GY, Perry A, Harding B et al (2019) CDKN2A\/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. Neuropathol Appl Neurobiol 45:174\u2013178","journal-title":"Neuropathol Appl Neurobiol"},{"key":"7567_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Reviews Clin Oncol 15:731\u2013747","journal-title":"Nat Reviews Clin Oncol"},{"key":"7567_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000430956","volume":"82","author":"AP Becker","year":"2015","unstructured":"Becker AP, Scapulatempo-Neto C, Menezes WP, Clara C, Machado HR, Oliveira RS, Neder LRR (2015) Expression of Methylthioadenosine Phosphorylase (MTAP) in Pilocytic Astrocytomas. Pathobiology 82:84\u201389. https:\/\/doi.org\/10.1159\/000430956","journal-title":"Pathobiology"},{"key":"7567_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1227\/00006123-199201000-00011","volume":"30","author":"H Schneider Jr","year":"1992","unstructured":"Schneider H Jr, Raffel C, McComb JG (1992) Benign cerebellar astrocytomas of childhood. Neurosurgery 30:58\u201362 discussion 62 \u2013 3. https:\/\/doi.org\/10.1227\/00006123-199201000-00011","journal-title":"Neurosurgery"},{"key":"7567_CR26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/NEUONC\/NOW294","volume":"19","author":"SH Ramkissoon","year":"2017","unstructured":"Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O\u2019Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H, Delalle I, Goumnerova LK (2017) Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol 19:986\u2013996. https:\/\/doi.org\/10.1093\/NEUONC\/NOW294","journal-title":"Neuro Oncol"},{"key":"7567_CR27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","volume":"10","author":"M Clarke","year":"2020","unstructured":"Clarke M, Mackay A, Ismer B et al (2020) Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discov 10:942\u2013963. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1030","journal-title":"Cancer Discov"},{"key":"7567_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.6004\/jadpro.2020.11.4.9","volume":"11","author":"B Dunn","year":"2020","unstructured":"Dunn B, PharmD D (2020) Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion. J Adv Practitioner Oncol 11:418. https:\/\/doi.org\/10.6004\/jadpro.2020.11.4.9","journal-title":"J Adv Practitioner Oncol"},{"key":"7567_CR29","doi-asserted-by":"crossref","unstructured":"Gambella A, Senetta R, Collemi G et al (2020) NTRK Fusions in Central Nervous System Tumors: A Rare. but Worthy Target","DOI":"10.3390\/ijms21030753"},{"key":"7567_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/S40265-020-01459-W","volume":"81","author":"KS Rohrberg","year":"2021","unstructured":"Rohrberg KS, Lassen U (2021) Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. Drugs 81:445\u2013452. https:\/\/doi.org\/10.1007\/S40265-020-01459-W","journal-title":"Drugs"},{"key":"7567_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/S40272-020-00380-9","volume":"22","author":"DS Shulman","year":"2020","unstructured":"Shulman DS, DuBois SG (2020) The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs 22:189\u2013197. https:\/\/doi.org\/10.1007\/S40272-020-00380-9","journal-title":"Paediatr Drugs"},{"key":"7567_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/S41379-019-0324-7","volume":"33","author":"JP Solomon","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A et al (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33:38. https:\/\/doi.org\/10.1038\/S41379-019-0324-7","journal-title":"Mod Pathol"},{"key":"7567_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/15384047.2021.1899573","volume":"22","author":"L Deland","year":"2021","unstructured":"Deland L, Keane S, Olsson Bontell T et al (2021) Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib. Cancer Biol Ther 22:184\u2013195. https:\/\/doi.org\/10.1080\/15384047.2021.1899573","journal-title":"Cancer Biol Ther"},{"key":"7567_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/J.CCELL.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall S, Zapotocky M, Fukuoka K et al (2020) Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell 37:569\u2013583e5. https:\/\/doi.org\/10.1016\/J.CCELL.2020.03.011","journal-title":"Cancer Cell"},{"key":"7567_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40478-020-00980-z","volume":"8","author":"M Torre","year":"2020","unstructured":"Torre M, Vasudevaraja V, Serrano J et al (2020) Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun 8:107. https:\/\/doi.org\/10.1186\/s40478-020-00980-z","journal-title":"Acta Neuropathol Commun"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T18:39:35Z","timestamp":1658428775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["7567"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07567-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by local Ethics Committee of Barretos Cancer Hospital, Barretos (number HCB\/87362), and Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Brazil (HCRP\/212313) and is in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}